Industry vet Carrie Strom has been named new President and Global Chief Executive Officer (CEO) at Hugel Inc.
She is expected to be appointed to the Board of Directors following approval at a forthcoming shareholders’ meeting. Ms. Strom will start the newly established global CEO role on Oct. 13, 2025. The Hugel Inc. executive leadership team will report directly to Ms. Strom, including the recently appointed head of Hugel Korea, Daniel Chang.
Most recently, Ms. Strom served as Senior Vice President of AbbVie and Global President of Allergan Aesthetics from May 2020 to February 2025, where she managed the $5 billion aesthetics portfolio, including Botox Cosmetic and Juvéderm, across more than 50 global markets. Previously, she was Senior Vice President of Allergan’s US Medical Aesthetics business, and before that, she spent 11 years at Pfizer in various sales and marketing roles.
“I am honored to join Hugel as the CEO and look forward to working alongside the talented and dedicated employees, operating team, and board of directors,” says Ms. Strom in a news release. “Hugel offers market-leading aesthetic products driven by science and the highest quality, which have always been grounded in Korean beauty standards. My priority is to build on Hugel’s leadership in South Korea and transform it into a global aesthetics powerhouse, raising the bar for how we serve customers and patients around the world.”
Hugel markets its botulinum toxin products (known as Botulax or Letybo globally) in 69 countries and its dermal fillers in 53 countries.
“Ms. Strom is a proven enterprise leader who we are confident will lead Hugel to the next level,” adds Suk Cha, Chairman of the Hugel Board of Directors. “We look forward to accelerating our expansion in the Americas and other key global markets under her leadership.”
